Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP Global Chief Med Officer | March 28, 2022 | March 29, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date March 28, 2022 · Filed March 29, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,082 |
Reported balance
After 2022-03-28 transaction · row 1
1 source rowRow 1 · 2022-03-28 · Sale · Disposed 6,588 · Balance 28,082 F1: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 28, 2022 Filed Mar 29, 2022 20:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 6,588 | $43.68 | $287,763.84 |
DisclosureSEC source: 0001225208-22-005192 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,082 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:27 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003862 · doc4.xml · derivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,019 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:27 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 300 | $44.17 | $13,251.00 |
DisclosureSEC source: 0001225208-22-003862 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,670 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:27 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003862 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 6,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003295 · doc4.xml · derivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,540 Underlying: Common Stock · 6,540 shares Expires 2023-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F2 · derivative.exercise_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F2 · derivative.expiration_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F2 · balance_after: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003081 · doc4.xml · derivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,013 Underlying: Common Stock · 1,013 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 298 | $42.55 | $12,679.90 |
DisclosureSEC source: 0001225208-22-003081 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,951 Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003081 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002921 · doc4.xml · derivative · entry 6 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,076 Underlying: Common Stock · 1,037 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 305 | $42.55 | $12,977.75 |
DisclosureSEC source: 0001225208-22-002921 · doc4.xml · nonDerivative · entry 4 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,236 Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002921 · doc4.xml · nonDerivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002921 · doc4.xml · derivative · entry 5 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 1,250 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 367 | $42.83 | $15,718.61 |
DisclosureSEC source: 0001225208-22-002921 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,504 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:45 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002921 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 12,941 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002675 · doc4.xml · derivative · entry 5 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,941 Underlying: Common Stock · 12,941 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 4,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002675 · doc4.xml · derivative · entry 4 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,525 Underlying: Common Stock · 4,525 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002675 · doc4.xml · derivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,108 Underlying: Common Stock · 1,108 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 326 | $44.01 | $14,347.26 |
DisclosureSEC source: 0001225208-22-002675 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,621 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002675 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-001307 · doc4.xml · derivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,131 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 1, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 1, 2018, the first anniversary of the date of grant. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 919 | $43.50 | $39,976.50 |
DisclosureSEC source: 0001225208-22-001307 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,839 Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-001307 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:51 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 3,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-000113 · doc4.xml · derivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,649 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. F1 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. F1 · derivative.expiration_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:51 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,265 | $42.48 | $53,737.20 |
DisclosureSEC source: 0001225208-22-000113 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,627 Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:51 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-000113 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. Read SEC document |
| December 28, 2021 Filed Dec 29, 2021 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 7,018 | $43.21 | $303,247.78 |
DisclosureSEC source: 0001225208-21-015271 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,243 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004219 · doc4.xml · derivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,019 Underlying: Common Stock · 1,018 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 299 | $38.78 | $11,595.22 |
DisclosureSEC source: 0001225208-21-004219 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,553 Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004219 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 3,676 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003521 · doc4.xml · derivative · entry 4 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,676 Underlying: Common Stock · 3,676 shares Expires 2022-12-31 F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F4 · derivative.exercise_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F4 · derivative.expiration_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F4 · balance_after: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003521 · doc4.xml · derivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,026 Underlying: Common Stock · 1,012 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 298 | $38.03 | $11,332.94 |
DisclosureSEC source: 0001225208-21-003521 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,834 Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003521 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003175 · doc4.xml · derivative · entry 5 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,113 Underlying: Common Stock · 1,037 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 305 | $37.52 | $11,443.60 |
DisclosureSEC source: 0001225208-21-003175 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,120 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003175 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 16,080 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001225208-21-003175 · doc4.xml · derivative · entry 4 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,080 Underlying: Common Stock · 16,080 shares Expires 2031-02-17 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003175 · doc4.xml · derivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-02-17 F2 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002702 · doc4.xml · derivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,216 Underlying: Common Stock · 1,107 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 325 | $38.39 | $12,476.75 |
DisclosureSEC source: 0001225208-21-002702 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,388 Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002702 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 22:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,268 | $38.85 | $49,261.80 |
DisclosureSEC source: 0001225208-21-002241 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,606 Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 22:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 4,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002241 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,874 F1 · shares: On February 15, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2020 and subject to the completion of the concurrent three-year individual service period. On February 9, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-001535 · doc4.xml · derivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,131 Underlying: Common Stock · 3,130 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 1, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 1, 2018, the first anniversary of the date of grant. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 919 | $35.95 | $33,038.05 |
DisclosureSEC source: 0001225208-21-001535 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,556 Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-001535 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 6,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-000226 · doc4.xml · derivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,527 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020. F1 · derivative.exercise_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020. F1 · derivative.expiration_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,127 | $35.95 | $76,465.65 |
DisclosureSEC source: 0001225208-21-000226 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,345 Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 21:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 6,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-000226 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2020. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004160 · doc4.xml · derivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,037 Underlying: Common Stock · 1,018 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.